CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

tsr-022

mAbexperimental

Clinical trial activity

7 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
4
Phase 3
1
Phase 4
0

Earliest trial started Jul 1, 2016 (NCT02817633)

Timeline

2010s

  1. Jan 1, 2016

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2018

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • tsr-022

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06521567Phase 1/Phase 2 (Phase 2)Sep 13, 2024GlaxoSmithKline
NCT06238635Phase 2Mar 11, 2024GlaxoSmithKline, Harvard University
NCT04655976Phase 2/Phase 3 (Phase 3)Dec 8, 2020GlaxoSmithKline
NCT04139902Phase 2Dec 15, 2019Tesaro, University of Pittsburgh
NCT03680508Phase 2Oct 31, 2018University of Hawaii
NCT03307785Phase 1Oct 12, 2017Tesaro
NCT02817633Phase 1Jul 1, 2016Tesaro
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
GlaxoSmithKlineFor profit3222020
TesaroFor profit3222016
Harvard UniversityAcademic/Hospital1112024
University of HawaiiAcademic/Hospital1112018
University of PittsburghAcademic/Hospital1112019
5 organizations
Page 1 / 1